Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Aclaris Therapeutics Inc.

    NASDAQ: ACRS · Real-Time Price · USD
    1.47
    -0.06 (-3.92%)
    At close: Jun 13, 2025, 3:59 PM
    1.44
    -2.11%
    After-hours: Jun 13, 2025, 05:43 PM EDT

    Aclaris Therapeutics Statistics

    Share Statistics

    Aclaris Therapeutics has 108.28M shares outstanding. The number of shares has increased by 51.43% in one year.

    Shares Outstanding

    n/a
    		 108.28M

    Shares Change (YoY)

    n/a
    		 51.43%

    Shares Change (QoQ)

    n/a
    		 51.08%

    Owned by Institutions (%)

    n/a
    		 99.99%

    Shares Floating

    n/a
    		 92.28M

    Failed to Deliver (FTD) Shares

    n/a
    		 19

    FTD / Avg. Volume

    n/a
    		 n/a

    Short Selling Information

    The latest short interest is 4.7M, so 4.34% of the outstanding shares have been sold short.

    Short Interest

    n/a
    		 4.7M

    Short % of Shares Out

    n/a
    		 4.34%

    Short % of Float

    n/a
    		 5.17%

    Short Ratio (days to cover)

    n/a
    		 5.93

    Valuation Ratios

    The PE ratio is -1.45 and the forward PE ratio is -2.38. Aclaris Therapeutics's PEG ratio is -0.04.

    PE Ratio

    n/a
    		 -1.45

    Forward PE

    n/a
    		 -2.38

    PS Ratio

    n/a
    		 10.24

    Forward PS

    n/a
    		 2.8

    PB Ratio

    n/a
    		 1.23

    P/FCF Ratio

    n/a
    		 -9.49

    PEG Ratio

    n/a
    		 -0.04
    Financial Ratio History

    Enterprise Valuation

    Currently the Enterprise Value (EV) is not available for Aclaris Therapeutics.

    EV / Sales

    n/a
    		 n/a

    EV / EBITDA

    n/a
    		 n/a

    EV / EBIT

    n/a
    		 n/a

    EV / FCF

    n/a
    		 n/a

    Financial Position

    The company has a current ratio of 3.99, with a Debt / Equity ratio of 0.

    Current Ratio

    n/a
    		 3.99

    Quick Ratio

    n/a
    		 3.99

    Debt / Equity

    n/a
    		 0

    Debt / EBITDA

    n/a
    		 n/a

    Debt / FCF

    n/a
    		 n/a

    Interest Coverage

    n/a
    		 0

    Financial Efficiency

    Return on Equity is n/a and Return on Invested Capital is n/a.

    Return on Equity

    n/a
    		 n/a

    Return on Assets

    n/a
    		 n/a

    Return on Invested Capital

    n/a
    		 n/a

    Revenue Per Employee

    n/a
    		 $306,885.25

    Profits Per Employee

    n/a
    		 $-2,165,000

    Employee Count

    n/a
    		 61

    Asset Turnover

    n/a
    		 0.08

    Inventory Turnover

    n/a
    		 n/a

    Taxes

    Income Tax

    n/a
    		 n/a

    Effective Tax Rate

    n/a
    		 0%

    Stock Price Statistics

    The stock price has increased by 24.58% in the last 52 weeks. The beta is 0.42, so Aclaris Therapeutics's price volatility has been higher than the market average.

    Beta

    n/a
    		 0.42

    52-Week Price Change

    n/a
    		 24.58%

    50-Day Moving Average

    n/a
    		 1.32

    200-Day Moving Average

    n/a
    		 1.92

    Relative Strength Index (RSI)

    n/a
    		 53.41

    Average Volume (20 Days)

    n/a
    		 856,582

    Income Statement

    In the last 12 months, Aclaris Therapeutics had revenue of 18.72M and earned -132.06M in profits. Earnings per share was -1.71.

    Revenue

    n/a
    		 18.72M

    Gross Profit

    n/a
    		 3.46M

    Operating Income

    n/a
    		 -141.93M

    Net Income

    n/a
    		 -132.06M

    EBITDA

    n/a
    		 -51.72M

    EBIT

    n/a
    		 -52.53M

    Earnings Per Share (EPS)

    n/a
    		 -1.71
    Full Income Statement

    Balance Sheet

    The company has 24.57M in cash and 0 in debt, giving a net cash position of 24.57M.

    Cash & Cash Equivalents

    n/a
    		 24.57M

    Total Debt

    n/a
    		 n/a

    Net Cash

    n/a
    		 n/a

    Retained Earnings

    n/a
    		 -902.86M

    Total Assets

    n/a
    		 198.09M

    Working Capital

    n/a
    		 87.28M
    Full Balance Sheet

    Cash Flow

    In the last 12 months, operating cash flow was -20.07M and capital expenditures -121K, giving a free cash flow of -20.2M.

    Operating Cash Flow

    n/a
    		 -20.07M

    Capital Expenditures

    n/a
    		 -121K

    Free Cash Flow

    n/a
    		 -20.2M

    FCF Per Share

    n/a
    		 -0.26
    Full Cash Flow Statement

    Margins

    Gross margin is 18.49%, with operating and profit margins of -758.18% and -705.48%.

    Gross Margin

    n/a
    		 18.49%

    Operating Margin

    n/a
    		 -758.18%

    Pretax Margin

    n/a
    		 -705.48%

    Profit Margin

    n/a
    		 -705.48%

    EBITDA Margin

    n/a
    		 -276.28%

    EBIT Margin

    n/a
    		 -758.18%

    FCF Margin

    n/a
    		 -107.88%

    Dividends & Yields

    ACRS does not appear to pay any dividends at this time.

    Dividend Per Share

    n/a
    		 n/a

    Dividend Yield

    n/a
    		 n/a

    Dividend Growth (YoY)

    n/a
    		 n/a

    Payout Ratio

    n/a
    		 n/a

    Earnings Yield

    n/a
    		 n/a

    FCF Yield

    n/a
    		 n/a
    Dividend Details

    Analyst Forecast

    The average price target for ACRS is $8, which is 444.2% higher than the current price. The consensus rating is "Buy".

    Price Target

    n/a
    		 $8

    Price Target Difference

    n/a
    		 444.2%

    Analyst Consensus

    n/a
    		 Buy

    Analyst Count

    n/a
    		 8
    Stock Forecasts

    Fair Value

    There are several formulas that can be used to estimate the intrinsic value of a stock.

    Lynch Fair Value

    n/a
    		 n/a

    Lynch Upside

    n/a
    		 n/a

    Graham Number

    n/a
    		 n/a

    Graham Upside

    n/a
    		 n/a

    Scores

    Altman Z-Score

    n/a
    		 -5.08

    Piotroski F-Score

    n/a
    		 2

    Add to Watchlist